<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Onco Targets Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Onco Targets Ther</journal-id>
<journal-id journal-id-type="publisher-id">OTT</journal-id>
<journal-id journal-id-type="pmc">ott</journal-id>
<journal-title-group>
<journal-title>OncoTargets and therapy</journal-title>
</journal-title-group>
<issn pub-type="epub">1178-6930</issn>
<publisher>
<publisher-name>Dove</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32021260</article-id>
<article-id pub-id-type="pmc">6954829</article-id>
<article-id pub-id-type="publisher-id">235798</article-id>
<article-id pub-id-type="doi">10.2147/OTT.S235798</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Upregulated lncRNA THRIL/TNF-α Signals Promote Cell Growth and Predict Poor Clinical Outcomes of Osteosarcoma</article-title>
<alt-title alt-title-type="running-authors">Xu et al</alt-title>
<alt-title alt-title-type="running-title">Xu et al</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-3867-9648</contrib-id>
<name>
<surname>Xu</surname>
<given-names>Bo</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
<xref ref-type="author-notes" rid="FT0001"></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Jin</surname>
<given-names>Xinmeng</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
<xref ref-type="author-notes" rid="FT0001"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Tieyi</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Yan</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Shuyi</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-9697-1404</contrib-id>
<name>
<surname>Wu</surname>
<given-names>Liang</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ying</surname>
<given-names>Hui</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Zhi</given-names>
</name>
<xref ref-type="corresp" rid="AN0001"></xref>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<aff id="AFF0001"><label>1</label><institution>Department of Orthopaedics, Gongli Hospital of Pudong New Area</institution>, <addr-line>Shanghai</addr-line>
<addr-line>200135</addr-line>, <country>People’s Republic of China</country></aff>
</contrib-group>
<author-notes>
<corresp id="AN0001">Correspondence: Zhi Wang <institution>Department of Orthopaedics, Gongli Hospital of Pudong New Area</institution>, <addr-line>NO. 219 Miaopu Road, Pudong New Area</addr-line>, <addr-line>Shanghai</addr-line><addr-line>200135</addr-line>, <country>People’s Republic of China</country><phone>Tel +86 188 1782 1626</phone> Email bbswangzhi@163.com</corresp>
<fn id="FT0001">
<label>*</label>
<p>These authors contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>13</volume>
<fpage>119</fpage>
<lpage>129</lpage>
<history>
<date date-type="received">
<day>23</day>
<month>10</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>12</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 Xu et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Xu et al.</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
<license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<sec id="S2001">
<title>Background</title>
<p>The immunosuppressive facet and tumorigenic role of TNF-α have been revealed in osteosarcoma (OS). Long noncoding RNA THRIL is identified to regulate TNF-α expression and participates in immune response. Thus, investigations on the clinical expression pattern of THRIL/TNF-α signal in OS would provide a potential target premise for OS patients.</p>
</sec>
<sec id="S2002">
<title>Methods</title>
<p>We collected OS (n=83), nontumor tissues (n=37) and serum samples (n=83 for OS and n=40 for healthy control) to determine the expressions and clinical significance of THRIL/TNF-α signal. Knockdown of THRIL in OS cell lines MG63 and Saos2 in vitro and in vivo was performed to confirm its function in the development of OS.</p>
</sec>
<sec id="S2003">
<title>Results</title>
<p>Elevated expression of THRIL was associated with increased TNF-α levels in OS tissues and serum samples. Combination of THRIL and TNF-α in tissues showed a more efficient diagnostic value for OS patients than either of them. Moreover, high-expressed THRIL was associated with larger tumor size, advanced Enneking stage and lung metastasis, whereas high TNF-α expression was found in patients with high histologic grade and patients who simultaneously harbor high THRIL and TNF-α showed the worst overall survival and metastasis-free survival. TNF-α signals increased OS cell vitalities in vitro but knockdown of THRIL inhibited TNF-α expressions, leading to impaired cell vitality, increased apoptosis and also downregulated epithelial to mesenchymal transition (EMT) phenotype and the ability of invasion, but these processes were restored by the treatment of TNF-α. The oncogenic role of THRIL/TNF-α signal was also confirmed in the xenograft model of MG63 cells.</p>
</sec>
<sec id="S2004">
<title>Conclusion</title>
<p>Overexpressed THRIL and TNF-α promoted OS progression with efficient diagnostic and prognostic value. THRIL/TNF-α signal supported cell growth and EMT phenotype of OS cells in vitro and in vivo.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>lncRNA</kwd>
<kwd>THRIL</kwd>
<kwd>TNF-α</kwd>
<kwd>osteosarcoma</kwd>
<kwd>growth</kwd>
</kwd-group>
<funding-group>
<funding-statement>This work was supported by Key Discipline Construction Project of Pudong Health Bureau of Shanghai (Grant No. PWZxk2017-18 to TYY) and Discipline Construction Project of Pudong New Area Commission of Health and Family Planning (Grant No. PWYts2018-03 to TYY).</funding-statement>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="4"></table-count>
<ref-count count="28"></ref-count>
<page-count count="11"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S0001" sec-type="intro">
<title>Introduction</title>
<p>Osteosarcoma (OS) often occurs in children and adolescents with an incidence of 4.4 per million people worldwide and is the most common malignant bone tumor. Approximately 50% of all patients at the time of diagnosis develop metastases, which results in a high mortality rate despite improvements in radiotherapy, adjuvant chemotherapy and surgery.<xref ref-type="bibr" rid="CIT0001">1</xref>–<xref ref-type="bibr" rid="CIT0003">3</xref> Elucidation of the molecular basis of OS progression is conducive to developing effective therapeutic agents and improving OS patient’s prognosis.</p>
<p>Persistent inflammation is known to promote and exacerbate malignancy. An intrinsic (driven by genetic events that cause neoplasia) and an extrinsic (driven by inflammatory conditions which predispose to cancer) pathway link inflammation and cancer.<xref ref-type="bibr" rid="CIT0004">4</xref> Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine that coordinates tissue homeostasis by regulating cytokine production, cell survival, and cell death.<xref ref-type="bibr" rid="CIT0005">5</xref> Accumulating evidence indicated that, in addition to being produced by immune cells within the tumor-associated microenvironment, TNF-α can be produced by a wide variety of malignant cells, including OS cells.<xref ref-type="bibr" rid="CIT0006">6</xref> Li et al reported that TNF-α may enhance the adaptive immune resistance mediated by IFN-γ-induced B7-H1 in hepatocellular carcinoma cells.<xref ref-type="bibr" rid="CIT0007">7</xref> TNF-α expression in ovarian carcinoma varies by histologic subtype and provides some support for the role of inflammation in ovarian carcinogenesis.<xref ref-type="bibr" rid="CIT0008">8</xref> Besides, TNF-α also promoted OS progression by maintaining tumor cells in an undifferentiated state.<xref ref-type="bibr" rid="CIT0009">9</xref> Activation of TNF-α signal enhanced CRL4B E3 ligase activity and regulates cell cycle progression in human OS cells.<xref ref-type="bibr" rid="CIT0010">10</xref> TNF-α regulated IL-34 expression in osteosarcoma cells and contributes to OS growth by increasing the neo-angiogenesis and the recruitment of M2 macrophage.<xref ref-type="bibr" rid="CIT0011">11</xref> Thus, the regulator of TNF-α is essential for controlling its inflammation imbalance during cancer therapy of OS.</p>
<p>Long noncoding RNAs (lncRNAs) are encoded by a vast less explored region of the human genome and its disruption is intrinsically linked to diverse diseases including cell growth, inflammation and tumor metastasis.<xref ref-type="bibr" rid="CIT0012">12</xref> lncRNA THRIL (TNF-α and hnRNPL related immune-regulatory lincRNA) is essential for the induction of TNF-α expression. Knockdown of THRIL caused dysregulation of TNF-α during innate activation of THP1 macrophages and was correlated with the severity of symptoms in patients with Kawasaki disease, an acute inflammatory disease of childhood.<xref ref-type="bibr" rid="CIT0013">13</xref> Upregulated THRIL was demonstrated to aggravate lipopolysaccharide (LPS)-induced osteoarthritis cell injury model via activating JAK1/STAT3 and NF-κB pathways.<xref ref-type="bibr" rid="CIT0014">14</xref> Currently, the function of THRIL/TNF-α signal in cancer is unclear. One of the most prominent features of cancer is hypoxia, which was found to increase the THRIL expression.<xref ref-type="bibr" rid="CIT0015">15</xref> Therefore, considering the tumorigenic role of TNF-α in OS, the function and its clinical significance of THRIL/TNF-α signal needed to be investigated in OS patients.</p>
<p>In this study, we analyzed the expression pattern of THRIL/TNF-α in OS tissues and serum and further revealed its diagnostic and prognostic value. We found that THRIL and TNF-α were co-upregulated in OS patients and predicted poor clinical outcomes. Knockdown of THRIL was performed in vitro and in vivo to confirm its role in OS growth and metastasis.</p>
</sec>
<sec id="S0002">
<title>Materials and Methods</title>
<sec id="S0002-S2001">
<title>Ethics and Sample Collection</title>
<p>All methods used for this study were approved by the Ethics Committee of Gongli Hospital of Pudong New Area, and this study was conducted in accordance with the Declaration of Helsinki. The OS tissues and serum samples (n=83), nontumor tissues (n=37) and serum from healthy subjects were obtained from patients who had undergone surgical resection of OS in the Gongli Hospital of Pudong New Area and other hospitals in Acknowledgments. We confirmed that all patients provided written informed consent. The median age was 22 years and the median of tumor size was 8 cm, and 22 in 83 patients were found with lung metastases. The tumor stages were confirmed according to the Enneking staging system (ESS). The tissues or serum samples were isolated from surgical removal or patients’ blood and then stored at −80°C until use. All the patients were followed-up until 20 April 2019. The minimum follow-up time is 3 months and the maximum follow-up time is 58 months (median: 26 months). The high or low expressions of THRIL/TNF-α were defined by the median of its expression.</p>
</sec>
<sec id="S0002-S2002">
<title>RNA Extraction and RT-Q-PCR</title>
<p>Total RNA was extracted from clinical specimens or cells via the TRIzol reagent (Invitrogen, USA), A260/A280 nm &gt;1.8 was qualified for quantitative analysis. Then, RNAs were transcribed into cDNA using superscriptase II (Invitrogen, USA) according to the manufacturer’s instructions. The cDNA was subjected to real time-polymerase chain reaction using Power SYBR<sup>®</sup> Green PCR Master Mix (Invitrogen, USA). The following primers were used: THRIL-F: GAGTGCAGTGGCGTGATCTC, R: AAAATTAGTCAGGCATGGTGGTG; TNF-α-F: CCTCTCTCTAATCAGCCCTCTG; R: GAGGACCTGGGAGTAGATGAG; Bcl-2-F: GGTGGGGTCATGTGTGTGG, R: CGGTTCAGGTACTCAGTCATCC; E-cadherin-F: CGAGAGCTACACGTTCACGG, R: GGGTGTCGAGGGAAAAATAGG; Vimentin-F: GACGCCATCAACACCGAGTT, R: CTTTGTCGTTGGTTAGCTGGT. The expression levels of genes were estimated via 2<sup>−ΔΔCt</sup> method and were normalized to GAPDH for gene expression. Each sample was measured in triplicate.</p>
</sec>
<sec id="S0002-S2003">
<title>ELISA</title>
<p>The serum levels of TNF-α were qualified by Human TNF-α ELISA kit (Cat#:EHC103a) according to the manufacturer’s instructions. The detection sensitivity was 7.8 pg/mL. All samples were tested by duplication, and absorbency was measured at 620 nm by a microplate reader.</p>
</sec>
<sec id="S0002-S2004">
<title>Cell Culture and Reagents</title>
<p>Human OS cell lines MG63 and Saos2 were obtained from the American Type Culture Collection (ATCC) and cultured in DMEM supplement with 10% FBS (GIBCO) and 1% penicillin/streptomycin. All the cells were cultured at 37°C water-saturated 5% CO2 atmosphere. siRNA-THRIL or negative control was conducted by RiboBio (Guangzhou, china), siRNA-THRIL-1: 5ʹ- GCTCTATGCACAGATAAATTT -3ʹ; siRNA-THRIL-2: 5ʹ- GCTCAGTCGTGTTTATTAATT -3ʹ; siRNA-TNFR1: 5ʹ-CAAAGGAACCUACUUGUACUU-3ʹ. Human recombinant TNF-α was purchased from Preoteintech (#HZ-1014, WUHAN, China). The antibody to E-cadherin and Vimentin were obtained from Abcam (USA).</p>
</sec>
<sec id="S0002-S2005">
<title>Estimation of Cell Growth</title>
<p>MG63 and Saos2 cells were transfected of siRNA-THRIL with/without the treatment of TNF-α (50 ng/mL) for 48 h, the cell vitality was determined by CCK-8. Briefly, cells were harvested and washed with PBS, and then cell counting kit-8 (Kumamoto, Japan) mixed with DMEM was used for cell viability assay according to the manufacturer’s instructions., and the absorbance was measured at 450 nm by a microplate reader. In addition, apoptosis was determined by flow cytometry. Briefly, cells were stained with 2 μL of annexin V mixed with 2 μL of propidium iodide (PI, eBioscience) were used according to the manufacturer’s instructions and were analyzed using a flow cytometry.</p>
</sec>
<sec id="S0002-S2006">
<title>Transwell Assay</title>
<p>To determine the role of THRIL in invasion of OS cells, 2×10<sup>4</sup> cells after transfection were suspended with 200 µL of serum-free medium. The Corning Polycarbonate Membrane Insert transwell chambers (Product #3422, Corning Costar Corp, Cambridge, MA, USA) were used to perform invasion assays. The Transwell membranes were pre-coated with Matrigel (BD Biosciences, USA) at 37°C for at least 2 hrs to form a reconstructed basement membrane. After incubation, cells at the top chamber were removed with cotton swabs, and those on the lower surface were fixed with methanol, stained by crystal violet and counted under an inverted microscope.</p>
</sec>
<sec id="S0002-S2007">
<title>Immunofluorescence Assays</title>
<p>MG63 and Saos2 cells with THRIL knockdown were cultured in a plastic chamber on microscope glass slides (Millicell EZ Slide, Millipore, Billerica, MA, USA) with TNF-α (50 ng/mL) stimulation for 48 hrs. The cells were then washed in PBS, fixed in 4% paraformaldehyde for 10 mins at room temperature, permeabilized with triton X-100 0.1% for 20 mins. The cells were incubated with primary antibody against E-cadherin and Vimentin for 120 mins. After washings, Alexa Fluor 488/594 secondary antibody was added for 90 mins at room temperature. Nuclei were stained with DAPI, which was observed under an FV10i confocal microscope (OLYMPUS, Tokyo, Japan).</p>
</sec>
<sec id="S0002-S2008">
<title>Tumor Model</title>
<p>To investigate the role of THRIL in the OS development, the xenograft model of human MG63 cells was established, MG63 cells were transfected with lentivirus vector of siRNA-THRIL, or negative control, 2×10<sup>6</sup> conditional MG63 cells were subcutaneously injected in rear flank of nude mice (6 per group), TNF-α (500 ng/mice) was treated i.p. twice a week for 3 weeks. The tumor sizes were measured 3 days apart and the tumor volumes were calculated: V (cm<sup>3</sup>) = width<sup>2</sup> (cm<sup>2</sup>) * length (cm)/2. The animal study was approved by institutional animal research committee of Gongli Hospital of Pudong New Area and that animals were cared for following the guidelines for use and care of laboratory animals.</p>
</sec>
<sec id="S0002-S2009">
<title>Statistical Analyses</title>
<p>The results are analyzed by the Statistical Package for Social Sciences version 16.0 (SPSS 16.0, SPSS Inc., Chicago, IL, USA) and the Prism statistical software package (Version 5.0, Graphpad Software Inc.). Kolmogorov–Smirnov and Shapiro–Wilk tests showed that the expression of THRIL/TNF-α did not follow a normal distribution. The Mann–Whitney <italic>U</italic>-test was used to compare the two groups (e.g., normal versus OS) and the differences between more than two groups were analyzed by the Kruskal–Wallis test. The receiver operating characteristic (ROC) curve was used to analyze its diagnostic value. Correlations between the expression of THRIL/TNF-α were analyzed by Spearman’s Rho analysis. Correlations between THRIL/TNF-α and clinicopathological characters were analyzed by Pearson Chi-square. Kaplan–Meier survival curves and the log-rank statistic were used to analyze the prognostic significance of THRIL/TNF-α. Cox proportional hazard regression was used for univariate and multivariate analysis of overall survival according to THRIL/TNF-α expression. <italic>P</italic>&lt;0.05 was considered statistically significant. All experiments were performed at least 3 times.</p>
</sec>
</sec>
<sec id="S0003">
<title>Results</title>
<sec id="S0003-S2001">
<title>THRIL Is Upregulated in OS and Positively Correlates with TNF-α</title>
<p>We first determined the expression of THRIL and TNF-α during the development of OS. THRIL and TNF-α were found to be upregulated in OS tissues (n=83) when compared to which in nontumor tissues (n=37) (<xref ref-type="fig" rid="F0001">Figure 1A</xref> and <xref ref-type="fig" rid="F0001">B</xref>). The enhanced TNF-α level was confirmed in the serum derived from OS patients (n=83) when compared with independent healthy subjects (n=40) (<xref ref-type="fig" rid="F0001">Figure 1C</xref>). Since THRIL could regulate TNF-α expression, we analyzed the correlation between THRIL and TNF-α. The results showed that THRIL is positively associated with TNF-α in OS tissues and serum (<xref ref-type="fig" rid="F0001">Figure 1D</xref> and <xref ref-type="fig" rid="F0001">E</xref>), suggesting that THRIL/TNF-α signal participated in the OS development.<fig fig-type="figure" id="F0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The expressions of THRIL and TNF-α in OS tissues and serum. (<bold>A</bold> and <bold>B</bold>) The mRNA levels of THRIL and TNF-α were analyzed in OS tissues (n=83) and nontumor tissues (n=37) by Q-PCR. (<bold>C</bold>) The serum TNF-α level was confirmed in the serum derived from OS patients (n=83) and independent healthy subjects (n=40) by ELISA. (<bold>D</bold> and <bold>E</bold>) The correlation between THRIL and TNF-α in OS tissues and serum was determined. (<bold>F</bold>) ROC curves were performed to evaluate the diagnostic role of THRIL and TNF-α alone, or THRIL/TNF-α combination. ***<italic>P</italic> &lt; 0.001, data represent the means ± SD.</p></caption><graphic content-type="print-only" xlink:href="OTT-13-119-g0001"></graphic></fig></p>
<p>The receiver operating characteristic (ROC) curve suggests that THRIL (AUC=0.773) and TNF-α (AUC=0.794) are good diagnostic markers to discriminate OS patients from healthy people, but combined with two factors showed more predominant diagnostic value (AUC=0.852) (<xref ref-type="fig" rid="F0001">Figure 1F</xref>).</p>
</sec>
<sec id="S0003-S2002">
<title>Elevated Expression of THRIL and TNF-α Occurs in OS Patients with Advanced Tumor Progression</title>
<p>Considering the upregulated THRIL/TNF-α signal in OS samples, we next determined the clinical significance of THRIL/TNF-α in OS. The expression of THRIL/TNF-α was divided into High and Low groups by median. The results showed that patients with larger tumor size, advanced Enneking stage and distant metastasis have higher THRIL levels in OS tissues. However, THRIL showed no relationships with gender, age, anatomic site and histology grade. Elevated TNF-α level was found in patients with high histology grade, which was consistent with the previous findings that TNF-α promoted OS progression by maintaining tumor cells in an undifferentiated state (<xref ref-type="table" rid="T0001">Table 1</xref>).<table-wrap id="T0001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Correlations Between the Expressions of THRIL and TNF-α with Clinicalpathologic Characteristics in OS Patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristics</th><th colspan="1" rowspan="1"></th><th colspan="2" rowspan="1">THRIL</th><th colspan="1" rowspan="1"><italic>P</italic></th><th colspan="1" rowspan="1">χ<sup>2</sup></th><th colspan="2" rowspan="1">TNF-α</th><th colspan="1" rowspan="1"><italic>P</italic></th><th colspan="1" rowspan="1">χ<sup>2</sup></th></tr><tr><th colspan="1" rowspan="1">n</th><th colspan="1" rowspan="1">Low (n/%)</th><th colspan="1" rowspan="1">High (n/%)</th><th colspan="1" rowspan="1">Low (n/%)</th><th colspan="1" rowspan="1">High (n/%)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>Gender</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Male</td><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">19(48.72)</td><td colspan="1" rowspan="1">20(51.28)</td><td colspan="1" rowspan="1">0.907</td><td colspan="1" rowspan="1">0.014</td><td colspan="1" rowspan="1">21(53.85)</td><td colspan="1" rowspan="1">18(46.15)</td><td colspan="1" rowspan="1">0.332</td><td colspan="1" rowspan="1">0.942</td></tr><tr><td colspan="1" rowspan="1"> Female</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">22(50)</td><td colspan="1" rowspan="1">22(50)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">19(43.18)</td><td colspan="1" rowspan="1">25(56.81)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Age</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> &lt;22</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">25(55.5)</td><td colspan="1" rowspan="1">20(44.4)</td><td colspan="1" rowspan="1">0.222</td><td colspan="1" rowspan="1">1.491</td><td colspan="1" rowspan="1">23(51.11)</td><td colspan="1" rowspan="1">22(48.89)</td><td colspan="1" rowspan="1">0.563</td><td colspan="1" rowspan="1">0.335</td></tr><tr><td colspan="1" rowspan="1"> ≥22</td><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">16(42.1)</td><td colspan="1" rowspan="1">22(57.89)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">17(44.74)</td><td colspan="1" rowspan="1">21(55.26)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Tumor size (cm)</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> ≤8</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">22(62.85)</td><td colspan="1" rowspan="1">13(37.14)</td><td colspan="1" rowspan="1">0.036*</td><td colspan="1" rowspan="1">4.386</td><td colspan="1" rowspan="1">18(51.42)</td><td colspan="1" rowspan="1">17(48.57)</td><td colspan="1" rowspan="1">0.614</td><td colspan="1" rowspan="1">0.254</td></tr><tr><td colspan="1" rowspan="1"> &gt;8</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">19(39.58)</td><td colspan="1" rowspan="1">29(60.42)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">22(45.83)</td><td colspan="1" rowspan="1">26(54.17)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Anatomic site</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Femur</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">24(46.15)</td><td colspan="1" rowspan="1">28(53.85)</td><td colspan="1" rowspan="1">0.61</td><td colspan="1" rowspan="1">0.988</td><td colspan="1" rowspan="1">21(40.38)</td><td colspan="1" rowspan="1">31(59.62)</td><td colspan="1" rowspan="1">0.128</td><td colspan="1" rowspan="1">2.315</td></tr><tr><td colspan="1" rowspan="1"> Tibia</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">9(50)</td><td colspan="1" rowspan="1">9(50)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">11(61.11)</td><td colspan="1" rowspan="1">7(38.89)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Other</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">8(61.54)</td><td colspan="1" rowspan="1">5(38.46)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">8(61.54)</td><td colspan="1" rowspan="1">5(38.46)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Enneking stage</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> I-IIA</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">23(67.65)</td><td colspan="1" rowspan="1">11(32.35)</td><td colspan="1" rowspan="1">0.006*</td><td colspan="1" rowspan="1">7.763</td><td colspan="1" rowspan="1">20(58.82)</td><td colspan="1" rowspan="1">14(41.17)</td><td colspan="1" rowspan="1">0.518</td><td colspan="1" rowspan="1">0.417</td></tr><tr><td colspan="1" rowspan="1"> IIB-III</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">18(36.73)</td><td colspan="1" rowspan="1">31(63.26)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">20(40.81)</td><td colspan="1" rowspan="1">29(59.18)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Histologic grade</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Low</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">21(52.5)</td><td colspan="1" rowspan="1">19(47.5)</td><td colspan="1" rowspan="1">0.586</td><td colspan="1" rowspan="1">0.297</td><td colspan="1" rowspan="1">24(60)</td><td colspan="1" rowspan="1">16(40)</td><td colspan="1" rowspan="1">0.038*</td><td colspan="1" rowspan="1">4.311</td></tr><tr><td colspan="1" rowspan="1"> High</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">20(46.51)</td><td colspan="1" rowspan="1">23(53.49)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">16(37.20)</td><td colspan="1" rowspan="1">27(62.79)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Lung metastasis</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> No</td><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">35(57.38)</td><td colspan="1" rowspan="1">26(42.62)</td><td colspan="1" rowspan="1">0.015*</td><td colspan="1" rowspan="1">5.862</td><td colspan="1" rowspan="1">29(47.54)</td><td colspan="1" rowspan="1">32(52.46)</td><td colspan="1" rowspan="1">0.843</td><td colspan="1" rowspan="1">0.039</td></tr><tr><td colspan="1" rowspan="1"> Yes</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">6(27.27)</td><td colspan="1" rowspan="1">16(72.73)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">11(50)</td><td colspan="1" rowspan="1">11(50)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Total</bold></td><td colspan="1" rowspan="1">83</td><td colspan="1" rowspan="1">41(100)</td><td colspan="1" rowspan="1">42(100)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">40(100)</td><td colspan="1" rowspan="1">43(100)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold> *<italic>P</italic> &lt;0.05, statistically significant by Chi-square test.</p></fn></table-wrap-foot></table-wrap>
</p>
<p>When the combination of THRIL and TNF-α was used for analysis, we found that the patients whose simultaneously high-expressed THRIL and TNF-α (THRIL<sup>High</sup>/TNF-α<sup>High</sup>) showed more advanced OS progression with a higher incidence of lung metastasis than patients with low-expressed THRIL and TNF-α (THRIL<sup>Low</sup>/TNF-α<sup>Low</sup>) (<xref ref-type="table" rid="T0002">Table 2</xref>).<table-wrap id="T0002" orientation="portrait" position="float"><label>Table 2</label><caption><p>Clinical Significance of Simultaneously High-Expressed or Low-Expressed THRIL and TNF-α in OS Patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristics</th><th colspan="1" rowspan="1">n</th><th colspan="1" rowspan="1">THRIL<sup>Low</sup>/TNF-α<sup>Low</sup> (n/%)</th><th colspan="1" rowspan="1">THRIL<sup>High</sup>/TNF-α<sup>High</sup> (n/%)</th><th colspan="1" rowspan="1"><italic>P</italic></th><th colspan="1" rowspan="1">χ<sup>2</sup></th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>Gender</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Male</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">12(40)</td><td colspan="1" rowspan="1">18(60)</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">1.791</td></tr><tr><td colspan="1" rowspan="1"> Female</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">14(58.33)</td><td colspan="1" rowspan="1">10(41.67)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Age</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> &lt;22</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">14(53.85)</td><td colspan="1" rowspan="1">12(46.15)</td><td colspan="1" rowspan="1">0.491</td><td colspan="1" rowspan="1">0.652</td></tr><tr><td colspan="1" rowspan="1"> ≥22</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">12(42.86)</td><td colspan="1" rowspan="1">16(57.14)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Tumor size(cm)</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> ≤8</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">18(72)</td><td colspan="1" rowspan="1">7(28)</td><td colspan="1" rowspan="1">0.001*</td><td colspan="1" rowspan="1">10.61</td></tr><tr><td colspan="1" rowspan="1"> &gt;8</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">8(27.59)</td><td colspan="1" rowspan="1">21(72.41)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Anatomic site</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Femur</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">22(52.38)</td><td colspan="1" rowspan="1">20(47.62)</td><td colspan="1" rowspan="1">0.467</td><td colspan="1" rowspan="1">1.523</td></tr><tr><td colspan="1" rowspan="1"> Tibia</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">3(37.50)</td><td colspan="1" rowspan="1">5(62.50)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Other</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">1(25)</td><td colspan="1" rowspan="1">3(75)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Enneking stage</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> I-IIA</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">16(72.73)</td><td colspan="1" rowspan="1">6(27.27)</td><td colspan="1" rowspan="1">0.003*</td><td colspan="1" rowspan="1">8.984</td></tr><tr><td colspan="1" rowspan="1"> IIB-III</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">10(31.25)</td><td colspan="1" rowspan="1">22(68.75)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Histologic grade</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Low</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">14(58.33)</td><td colspan="1" rowspan="1">10(41.67)</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">1.795</td></tr><tr><td colspan="1" rowspan="1"> High</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">12(40)</td><td colspan="1" rowspan="1">18(60)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Lung metastasis</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> No</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">22(59.46)</td><td colspan="1" rowspan="1">15(40.54)</td><td colspan="1" rowspan="1">0.014*</td><td colspan="1" rowspan="1">6.023</td></tr><tr><td colspan="1" rowspan="1"> Yes</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">4(23.53)</td><td colspan="1" rowspan="1">13(76.47)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Total</bold></td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">26(100)</td><td colspan="1" rowspan="1">28(100)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold> *<italic>P</italic> &lt;0.05, statistically significant by Chi-square test.</p></fn></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="S0003-S2003">
<title>High THRIL and TNF-α Levels Predict Short Overall Survival and Metastasis-Free Time</title>
<p>The prognostic role of THRIL/TNF-α signal was also analyzed. The results showed that high expression of THRIL predicted shorter overall survival time (<italic>P</italic>=0.024) and metastasis-free survival (MFS) (<italic>P</italic>=0.033) (<xref ref-type="fig" rid="F0002">Figure 2A</xref> and <xref ref-type="fig" rid="F0002">B</xref>), but TNF-α showed no impacts on overall survival time and metastasis-free time of OS patients (<xref ref-type="fig" rid="F0002">Figure 2C</xref> and <xref ref-type="fig" rid="F0002">D</xref>).<fig fig-type="figure" id="F0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The prognostic roles of THRIL and TNF-α in OS. The expressions of THRIL/TNF-α were divided into High and Low groups by median. (<bold>A</bold> and <bold>B</bold>) The overall survival time and metastasis-free time of OS patients were analyzed according to the THRIL expression. (<bold>C</bold> and <bold>D</bold>) The overall survival time and metastasis-free time of OS patients were analyzed according to the TNF-α expression. (<bold>E</bold> and <bold>F</bold>) The overall survival time and metastasis-free time of OS patients were analyzed according to the THRIL and TNF-α expression.</p></caption><graphic content-type="print-only" xlink:href="OTT-13-119-g0002"></graphic></fig></p>
<p>We further analyzed the survival time of patients with THRIL<sup>High</sup>/TNF-α<sup>High</sup>, the results indicated that, compared with THRIL alone, combination of THRIL and TNF-α was more efficient to predict the decreased survival time of OS patients (<xref ref-type="fig" rid="F0002">Figure 2E</xref> and <xref ref-type="fig" rid="F0002">F</xref>).</p>
</sec>
<sec id="S0003-S2004">
<title>THRIL Is an Independently Prognostic Factor for OS Patients</title>
<p>We further performed univariate and multivariate analyses, the results found that gender, age, anatomic site, Enneking stage, histologic grade and TNF-α were not independent prognostic indicators for overall survival time. In addition, the tumor size, lung metastasis and the expression of THRIL were independent prognostic factors for the overall survival time of patients with OS (<xref ref-type="table" rid="T0003">Table 3</xref>). However, THRIL was not an independent prognostic factor for metastasis-free survival of patients with OS (<xref ref-type="table" rid="T0004">Table 4</xref>).<table-wrap id="T0003" orientation="portrait" position="float"><label>Table 3</label><caption><p>Prognostic Factors in the Cox Proportional Hazard Model for Overall Survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Variables</th><th colspan="6" rowspan="1">Overall Survival</th></tr><tr><th colspan="1" rowspan="1"></th><th colspan="1" rowspan="1">HR</th><th colspan="1" rowspan="1">Univariate 95% CI</th><th colspan="1" rowspan="1">Sig</th><th colspan="1" rowspan="1">HR</th><th colspan="1" rowspan="1">Multivariate 95% CI</th><th colspan="1" rowspan="1">Sig.</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>Gender</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Male vs female</td><td colspan="1" rowspan="1">0.885</td><td colspan="1" rowspan="1">0.563–1.427</td><td colspan="1" rowspan="1">0.812</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Age</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> &lt;22 vs ≥22</td><td colspan="1" rowspan="1">1.223</td><td colspan="1" rowspan="1">0.734–1.891</td><td colspan="1" rowspan="1">0.438</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Tumor size(cm)</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> &lt;8 vs ≥8</td><td colspan="1" rowspan="1">2.863</td><td colspan="1" rowspan="1">1.233–3.675</td><td colspan="1" rowspan="1">0.013*</td><td colspan="1" rowspan="1">2.473</td><td colspan="1" rowspan="1">2.303–4.392</td><td colspan="1" rowspan="1">0.006*</td></tr><tr><td colspan="1" rowspan="1"><bold>Anatomic site</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Femur vs other</td><td colspan="1" rowspan="1">0.935</td><td colspan="1" rowspan="1">0.942–1.343</td><td colspan="1" rowspan="1">0.826</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Enneking stage</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">I-IIAvs. II B-III</td><td colspan="1" rowspan="1">2.173</td><td colspan="1" rowspan="1">1.694–4.726</td><td colspan="1" rowspan="1">0.031*</td><td colspan="1" rowspan="1">1.943</td><td colspan="1" rowspan="1">0.813–2.046</td><td colspan="1" rowspan="1">0.328</td></tr><tr><td colspan="1" rowspan="1"><bold>Histologic grade</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Low vs high</td><td colspan="1" rowspan="1">0.917</td><td colspan="1" rowspan="1">0.459–1.558</td><td colspan="1" rowspan="1">0.923</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Lung metastasis</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> - vs +</td><td colspan="1" rowspan="1">3.625</td><td colspan="1" rowspan="1">1.301–4.862</td><td colspan="1" rowspan="1">0.002*</td><td colspan="1" rowspan="1">4.115</td><td colspan="1" rowspan="1">2.263–6.345</td><td colspan="1" rowspan="1">0.001*</td></tr><tr><td colspan="1" rowspan="1"><bold>THRIL</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Low vs high</td><td colspan="1" rowspan="1">2.075</td><td colspan="1" rowspan="1">1.630–2.684</td><td colspan="1" rowspan="1">0.025*</td><td colspan="1" rowspan="1">2.347</td><td colspan="1" rowspan="1">1.349–3.758</td><td colspan="1" rowspan="1">0.023*</td></tr><tr><td colspan="1" rowspan="1"><bold>TNF-α</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Low vs high</td><td colspan="1" rowspan="1">1.234</td><td colspan="1" rowspan="1">0.676–1.602</td><td colspan="1" rowspan="1">0.463</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold> *<italic>P</italic> &lt;0.05, statistically significant.</p><p><bold>Abbreviations:</bold> HR, hazard ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="T0004" orientation="portrait" position="float"><label>Table 4</label><caption><p>Prognostic Factors in the Cox Proportional Hazard Model for Metastasis-Free Survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Variables</th><th colspan="6" rowspan="1">Metastasis-Free Survival</th></tr><tr><th colspan="1" rowspan="1"></th><th colspan="1" rowspan="1">HR</th><th colspan="1" rowspan="1">Univariate 95% CI</th><th colspan="1" rowspan="1">Sig</th><th colspan="1" rowspan="1">HR</th><th colspan="1" rowspan="1">Multivariate 95% CI</th><th colspan="1" rowspan="1">Sig.</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>Gender</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Male vs female</td><td colspan="1" rowspan="1">0.923</td><td colspan="1" rowspan="1">0.623–1.969</td><td colspan="1" rowspan="1">0.903</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Age</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> &lt;22 vs ≥22</td><td colspan="1" rowspan="1">1.058</td><td colspan="1" rowspan="1">0.822–1.358</td><td colspan="1" rowspan="1">0.828</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Tumor size(cm)</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> &lt;8 vs ≥8</td><td colspan="1" rowspan="1">2.266</td><td colspan="1" rowspan="1">1.384–3.294</td><td colspan="1" rowspan="1">0.033*</td><td colspan="1" rowspan="1">1.789</td><td colspan="1" rowspan="1">1.873–2.545</td><td colspan="1" rowspan="1">0.128</td></tr><tr><td colspan="1" rowspan="1"><bold>Anatomic site</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Femur vs other</td><td colspan="1" rowspan="1">0.867</td><td colspan="1" rowspan="1">0.683–1.225</td><td colspan="1" rowspan="1">0.774</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Enneking stage</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> I-IIAvs.IIB-III</td><td colspan="1" rowspan="1">1.984</td><td colspan="1" rowspan="1">1.213–2.685</td><td colspan="1" rowspan="1">0.053</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Histologic grade</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Low vs High</td><td colspan="1" rowspan="1">0.881</td><td colspan="1" rowspan="1">0.739–1.304</td><td colspan="1" rowspan="1">0.893</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"><bold>Lung metastasis</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> - vs +</td><td colspan="1" rowspan="1">2.782</td><td colspan="1" rowspan="1">1.426–3.678</td><td colspan="1" rowspan="1">0.012*</td><td colspan="1" rowspan="1">3.302</td><td colspan="1" rowspan="1">1.892–5.367</td><td colspan="1" rowspan="1">0.008*</td></tr><tr><td colspan="1" rowspan="1"><bold>THRIL</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Low vs high</td><td colspan="1" rowspan="1">1.976</td><td colspan="1" rowspan="1">1.567–3.869</td><td colspan="1" rowspan="1">0.038*</td><td colspan="1" rowspan="1">1.347</td><td colspan="1" rowspan="1">0.835–2.112</td><td colspan="1" rowspan="1">0.236</td></tr><tr><td colspan="1" rowspan="1"><bold>TNF-α</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> Low vs high</td><td colspan="1" rowspan="1">0.789</td><td colspan="1" rowspan="1">0.492–1.263</td><td colspan="1" rowspan="1">0.673</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold> *<italic>P</italic> &lt;0.05, statistically significant.</p><p><bold>Abbreviations:</bold> HR, hazard ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="S0003-S2005">
<title>Knockdown of THRIL Inhibits OS Growth and Invasion via TNF-α in vitro and in vivo</title>
<p>The function of TNF-α alone was investigated and found that the treatment of TNF-α (50 ng/mL) elevated the cell vitality of OS cells, which was consistent with previous reports<xref ref-type="bibr" rid="CIT0016">16</xref> (<xref ref-type="fig" rid="F0003">Figure 3A</xref>). Then, we performed knockdown of THRIL in two OS cell lines MG63 and Saos2 to confirm its pro-tumor function. The results indicated that knockdown of THRIL inhibited the expression of TNF-α by two siRNA. SiRNA-1 was selected for further study (<xref ref-type="fig" rid="F0003">Figure 3B</xref> and <xref ref-type="fig" rid="F0003">C</xref>). To confirm the role of TNF-α signal for THRIL function, we inhibited TNF receptor (TNFR) in OS cells in response to TNF-α treatment and THRIL knockdown. The results demonstrated that the OS cells with THRIL knockdown showed impaired cell vitality, but the treatment of TNF-α (50 ng/mL) to the OS cells with THRIL knockdown could restore its cell vitality, which was dependent on TNFR signals. Inhibition of TNFR by siRNA suppressed the function of TNF-α in the OS cells with THRIL knockdown. Thus, the function of THRIL is dependent on TNF-α/TNFR signals (<xref ref-type="fig" rid="F0003">Figure 3D</xref> and <xref ref-type="fig" rid="F0003">E</xref>).<fig fig-type="figure" id="F0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Knockdown of THRIL inhibits cell growth and invasion of OS cell via TNF-α. (<bold>A</bold>) TNF-α (50 ng/mL) was treated to two OS cell lines MG63 and Saos2 and the cell vitality was determined. (<bold>B</bold> and <bold>C</bold>) Knockdown of THRIL in two OS cell lines MG63 and Saos2 via siRNA, and the expressions of THRIL/TNF-α were determined at 24 hrs by Q-PCR. (<bold>D</bold> and <bold>E</bold>) After knockdown of THRIL/TNFR1, the cells were treated with or without TNF-α (50 ng/mL) for 48 h, and cell vitality and apoptosis of two cell lines were analyzed by CCK-8. (<bold>F</bold>) After knockdown of THRIL with or without TNF-α stimulation, the cell apoptosis was analyzed by flow cytometry. (<bold>G</bold>) Transwell assay was performed to determine the invasion of OS cell after THRIL knockdown. Five random views were selected to count the cells. (<bold>H</bold>) Immunofluorescence assay was performed to analyze the expression of E-cadherin (Green) and Vimentin (Red) in two cell lines. (<bold>I</bold>) 2×10<sup>6</sup> conditional MG63 cells were transfected with a lentivirus vector of siRNA-THRIL or negative control and were subcutaneously injected in the rear flank of nude mice (6 per group). TNF-α (500 ng/mice) was treated i.p. The mean tumor size (mm<sup>3</sup>) was analyzed. (<bold>J</bold>) The expressions of THRIL, TNF-α, Bcl-2, E-cadherin and Vimentin in tumor tissues were determined by Q-PCR. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001. Data represent the means ± SD.</p></caption><graphic content-type="print-only" xlink:href="OTT-13-119-g0003"></graphic></fig></p>
<p>Thus, we further investigated the role of THRIL/TNF-α signal in cell apoptosis and metastasis of two OS cell lines. Inhibition of THRIL induced apoptosis in 48 h, which could be restored by the treatment of TNF-α (50 ng/mL), indicating that THRIL promoted OS growth via TNF-α (<xref ref-type="fig" rid="F0003">Figure 3F</xref>). The ability of invasion was also determined by Transwell assay, we found that knockdown of THRIL inhibited OS invasion but the addition of TNF-α abrogated this suppression and upregulated the ability of invasion (<xref ref-type="fig" rid="F0003">Figure 3G</xref>). This process might be attributed to changed EMT phenotype of OS cells. Inhibition of THRIL downregulated the expression of vimentin but TNF-α (50 ng/mL) could restore the levels of vimentin in MG63 and Saos2 cells (<xref ref-type="fig" rid="F0003">Figure 3H</xref>).</p>
<p>We also investigated the role of THRIL in vivo. The results showed that the mice with THRIL knockdown by lentivirus have smaller tumor volume than that with a negative control. However, treatment of TNF-α (500 ng/mice) could restore the antitumor function of THRIL knockdown (<xref ref-type="fig" rid="F0003">Figure 3I</xref>). In line with this, the antiapoptosis gene Bcl-2 and Vimentin were downregulated by THRIL knockdown, but were recovered by the treatment of TNF-α in vivo (<xref ref-type="fig" rid="F0003">Figure 3J</xref>).</p>
</sec>
</sec>
<sec id="S0004">
<title>Discussion</title>
<p>Continuous exposure to inflammatory cytokines (such as TNF-α, IL-6, IL-8 and IL-1β, etc.) is known to cause tumorigenesis.<xref ref-type="bibr" rid="CIT0004">4</xref> TNF-α can be produced by leukemia cells to mediate cell survival and higher TNF-α concentrations in leukemia patients were correlated with heavier fatigue and poorer quality of life.<xref ref-type="bibr" rid="CIT0017">17</xref> TNF-α also promoted OS progression by maintaining tumor cells in an undifferentiated state.<xref ref-type="bibr" rid="CIT0009">9</xref> Many lncRNAs have been reported to regulate and control the balance of inflammation during several diseases. Li et al reported that THRIL bound specifically to heterogenous nuclear ribonucleoprotein L (hnRNPL) and formed a functional THRIL–hnRNPL complex that regulated transcription of the TNF-α gene by binding to its promoter. Transcriptome analysis revealed that THRIL was required for expression of many immune-response genes, including TNF-α<xref ref-type="bibr" rid="CIT0013">13</xref> We here identified the positive regulatory role of THRIL to TNF-α in OS cells. Knockdown of THRIL inhibited TNF-α expression and TNF-α-induced OS cell growth. Similarly, NF-κB-interacting lncRNA (NKILA) was highly induced in response to IL-1β and TNF-α stimulation.<xref ref-type="bibr" rid="CIT0018">18</xref> lncRNA Mirt2 functioned as a checkpoint to prevent aberrant activation of inflammation and was a potential regulator of macrophage polarization via attenuating Lys63 (K63)-linked ubiquitination of TRAF6, thus inhibiting activation of NF-κB and MAPK pathways.<xref ref-type="bibr" rid="CIT0019">19</xref> lnc-IL7R was capable of diminishing the LPS-induced inflammatory response via repressing LPS-induced E-selectin, VCAM-1, IL-6, and IL-8.<xref ref-type="bibr" rid="CIT0020">20</xref> However, the inflammatory lncRNAs in during the development of OS remains unclear. TGF-β or TNF-α treatment could enhance the expression of oncogenic lncRNA UCA1 for cell growth, migration and invasion of OS cells.<xref ref-type="bibr" rid="CIT0021">21</xref> We also found that TNF-α-induced EMT phenotype could be restored by THRIL knockdown via upegulation of E-cadherin and downregulation of Vimentin. Thus, controlling chronic inflammation is crucial to prevent tumor progression.</p>
<p>Currently, the researches on the role of THRIL focused on inflammation-related diseases. Upregulated THRIL was found to predict increased risk of acute respiratory distress syndrome and positively correlates with disease severity, inflammation, and mortality in sepsis patients.<xref ref-type="bibr" rid="CIT0022">22</xref> In this study, we found that lncRNA THRIL upregulated TNF-α in tumor tissue and serum of OS patients, which could be efficient diagnostic and prognostic biomarker. THRIL was also positively associated with CRP, PCT, TNF-α, and IL-1β levels in sepsis patients.<xref ref-type="bibr" rid="CIT0022">22</xref> In Kawasaki disease, an acute inflammatory disease of childhood, THRIL was correlated with the severity of symptoms of patients.<xref ref-type="bibr" rid="CIT0013">13</xref> In hypoxia-induced injuries, THRIL inhibition represents a protective effect against hypoxia-induced injuries in H9C2 cells.<xref ref-type="bibr" rid="CIT0022">22</xref> However, THRIL RNA expression was significantly decreased in autism spectrum disorder (ASD) children, although TNF-α, IL-1β and IL-17 were significantly increased in ASD children.<xref ref-type="bibr" rid="CIT0023">23</xref> THRIL was significantly decreased in patients with type 2 diabetes mellitus compared to control subjects, which were positively correlated with poor glycemic control, insulin resistance.<xref ref-type="bibr" rid="CIT0024">24</xref> But the investigation of THRIL in cancer is limited. We found that the expression of THRIL was increased in OS patients. High-expressed THRIL was positively associated with advanced OS progression including tumor size, clinical stage and lung metastasis. Patients with upregulated THRIL have shorter overall survival time and metastasis-free time. Esfandi et al investigated the role of THRIL in lung cancer, but the expression of THRIL was not changed in lung cancer samples and their corresponding adjacent noncancerous tissues.<xref ref-type="bibr" rid="CIT0025">25</xref> Similar results were also reported in bladder cancer.<xref ref-type="bibr" rid="CIT0026">26</xref> Interestingly, Wang et al found a significantly decreased risk of precancerous cervical lesions for the THRIL rs7133268 AG genotype (odds ratio adjusted=0.63).<xref ref-type="bibr" rid="CIT0027">27</xref> These findings suggested the content-dependent role of THRIL during disease progression.</p>
<p>The function of THRIL was related to its regulatory role of TNF-α. We here confirmed that THRIL was positively associated with upregulated TNF-α in OS tissues and serum. Combination of THRIL and TNF-α showed prominent diagnostic value for OS patients. However, TNF-α exerts diverse functions in cancer, other than the role of promoting tumor death. For example, TNF-α could promote cell growth, migration and invasion of MCF-7 estrogen receptor (ER)-positive and MDA-MB-231 (triple-negative) breast cancer cell lines, partially by inducing the expression of MMPs.<xref ref-type="bibr" rid="CIT0028">28</xref> Consistently, we here found that knockdown of THRIL in vivo could inhibit cell growth and invasion, which was abrogated by the treatment of TNF-α. The clinical analysis also showed that patients with high expression of TNF-α have high histology grade and THRIL<sup>High</sup>/TNF-α<sup>High</sup> predicted worst overall survival and metastasis-free survival of OS patients.</p>
<p>In sum, we here investigated the clinical role and function of upregulated THRIL/TNF-α signal in OS and found that patients with THRIL<sup>High</sup>/TNF-α<sup>High</sup> showed poor clinical outcomes and short metastasis-free survival time, which was involved with THRIL/TNF-α signal-supported cell growth and EMT phenotype for OS progression.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>We would like to thank Shanghai Changzheng Hospital, Shanghai Ninth People’s Hospital and Shanghai Ruijin Hospital for their precious OS samples.</p>
</ack>
<sec id="S0005">
<title>Author Contributions</title>
<p>All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.</p>
</sec>
<sec id="S0006" sec-type="COI-statement">
<title>Disclosure</title>
<p>The authors report no conflicts of interest in this work.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="CIT0001">
<label>1.</label>
<mixed-citation publication-type="journal"><string-name><surname>Toki</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kobayashi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Yoshida</surname>
<given-names>A</given-names></string-name>, et al. <article-title>A clinical comparison between dedifferentiated low-grade osteosarcoma and conventional osteosarcoma</article-title>. <source/><italic toggle="yes">Bone Joint J</italic>. <year>2019</year>;<volume>101-B</volume>(<issue>6</issue>):<fpage>745</fpage>–<lpage>752</lpage>. doi:<pub-id pub-id-type="doi">10.1302/0301-620X.101B6.BJJ-2018-1207.R1</pub-id><pub-id pub-id-type="pmid">31154837</pub-id></mixed-citation>
</ref>
<ref id="CIT0002">
<label>2.</label>
<mixed-citation publication-type="journal"><string-name><surname>Ahmed</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Zamzam</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kamel</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Effect of timing of pulmonary metastasis occurrence on the outcome of metastasectomy in osteosarcoma patients</article-title>. <source/><italic toggle="yes">Journal of Pediatric Surgery</italic>. <year>2019</year>;<volume>54</volume>(<issue>4</issue>):<fpage>775</fpage>–<lpage>779</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpedsurg.2018.06.019</pub-id><pub-id pub-id-type="pmid">30005831</pub-id></mixed-citation>
</ref>
<ref id="CIT0003">
<label>3.</label>
<mixed-citation publication-type="journal"><string-name><surname>Kumar</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kumar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Malhotra</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Patel</surname>
<given-names>S</given-names></string-name>. <article-title>Primary osteosarcoma in the elderly revisited: current concepts in diagnosis and treatment</article-title>. <source/><italic toggle="yes">Curr Oncol Rep</italic>. <year>2018</year>;<volume>20</volume>(<issue>2</issue>):<fpage>13</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s11912-018-0658-1</pub-id><pub-id pub-id-type="pmid">29492676</pub-id></mixed-citation>
</ref>
<ref id="CIT0004">
<label>4.</label>
<mixed-citation publication-type="journal"><string-name><surname>Capece</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Verzella</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Tessitore</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Alesse</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Capalbo</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Zazzeroni</surname>
<given-names>F</given-names></string-name>. <article-title>Cancer secretome and inflammation: the bright and the dark sides of NF-kappaB</article-title>. <source/><italic toggle="yes">Semin Cell Dev Biol</italic>. <year>2018</year>;<volume>78</volume>:<fpage>51</fpage>–<lpage>61</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.semcdb.2017.08.004</pub-id><pub-id pub-id-type="pmid">28779979</pub-id></mixed-citation>
</ref>
<ref id="CIT0005">
<label>5.</label>
<mixed-citation publication-type="journal"><string-name><surname>Salomon</surname>
<given-names>BL</given-names></string-name>, <string-name><surname>Leclerc</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tosello</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ronin</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Piaggio</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Cohen</surname>
<given-names>JL</given-names></string-name>. <article-title>Tumor necrosis factor alpha and regulatory T cells in oncoimmunology</article-title>. <source/><italic toggle="yes">Front Immunol</italic>. <year>2018</year>;<volume>9</volume>:<fpage>444</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2018.00444</pub-id><pub-id pub-id-type="pmid">29593717</pub-id></mixed-citation>
</ref>
<ref id="CIT0006">
<label>6.</label>
<mixed-citation publication-type="journal"><string-name><surname>Ciebiera</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wlodarczyk</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zgliczynska</surname>
<given-names>M</given-names></string-name>, et al. <article-title>The role of tumor necrosis factor alpha in the biology of uterine fibroids and the related symptoms</article-title>. <source/><italic toggle="yes">Int J Mol Sci</italic>. <year>2018</year>;<volume>19</volume>:<fpage>12</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms19123869</pub-id></mixed-citation>
</ref>
<ref id="CIT0007">
<label>7.</label>
<mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>N</given-names></string-name>, et al. <article-title>Cross-talk between TNF-alpha and IFN-gamma signaling in induction of B7-H1 expression in hepatocellular carcinoma cells</article-title>. <source/><italic toggle="yes">Cancer Immunol Immunother</italic>. <year>2018</year>;<volume>67</volume>(<issue>2</issue>):<fpage>271</fpage>–<lpage>283</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00262-017-2086-8</pub-id><pub-id pub-id-type="pmid">29090321</pub-id></mixed-citation>
</ref>
<ref id="CIT0008">
<label>8.</label>
<mixed-citation publication-type="journal"><string-name><surname>Gupta</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Babic</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Beck</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>Terry</surname>
<given-names>K</given-names></string-name>. <article-title>TNF-alpha expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?</article-title>. <source/><italic toggle="yes">Human pathol</italic>. <year>2016</year>;<volume>54</volume>:<fpage>82</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">27068525</pub-id></mixed-citation>
</ref>
<ref id="CIT0009">
<label>9.</label>
<mixed-citation publication-type="journal"><string-name><surname>Mori</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Sato</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Miyamoto</surname>
<given-names>K</given-names></string-name>, et al. <article-title>TNFalpha promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state</article-title>. <source/><italic toggle="yes">Oncogene</italic>. <year>2014</year>;<volume>33</volume>(<issue>33</issue>):<fpage>4236</fpage>–<lpage>4241</lpage>. doi:<pub-id pub-id-type="doi">10.1038/onc.2013.545</pub-id><pub-id pub-id-type="pmid">24336323</pub-id></mixed-citation>
</ref>
<ref id="CIT0010">
<label>10.</label>
<mixed-citation publication-type="journal"><string-name><surname>Zhang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lao</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Z</given-names></string-name>. <article-title>Activation of TNF-alpha/NF-kappaB axis enhances CRL4B(DCAF)(11) E3 ligase activity and regulates cell cycle progression in human osteosarcoma cells</article-title>. <source/><italic toggle="yes">Mol Oncol</italic>. <year>2018</year>;<volume>12</volume>(<issue>4</issue>):<fpage>476</fpage>–<lpage>494</lpage>. doi:<pub-id pub-id-type="doi">10.1002/1878-0261.12176</pub-id><pub-id pub-id-type="pmid">29377600</pub-id></mixed-citation>
</ref>
<ref id="CIT0011">
<label>11.</label>
<mixed-citation publication-type="journal"><string-name><surname>Segaliny</surname>
<given-names>AI</given-names></string-name>, <string-name><surname>Mohamadi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dizier</surname>
<given-names>B</given-names></string-name>, et al. <article-title>Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment</article-title>. <source/><italic toggle="yes">Int J Cancer</italic>
<year>2015</year>;<volume>137</volume>(<issue>1</issue>):<fpage>73</fpage>–<lpage>85</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.29376</pub-id><pub-id pub-id-type="pmid">25471534</pub-id></mixed-citation>
</ref>
<ref id="CIT0012">
<label>12.</label>
<mixed-citation publication-type="journal"><string-name><surname>Lin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>L</given-names></string-name>. <article-title>Long noncoding RNA in cancer: wiring signaling circuitry</article-title>. <source/><italic toggle="yes">Trends Cell Biol</italic>. <year>2018</year>;<volume>28</volume>(<issue>4</issue>):<fpage>287</fpage>–<lpage>301</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tcb.2017.11.008</pub-id><pub-id pub-id-type="pmid">29274663</pub-id></mixed-citation>
</ref>
<ref id="CIT0013">
<label>13.</label>
<mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Chao</surname>
<given-names>TC</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>KY</given-names></string-name>, et al. <article-title>The long noncoding RNA THRIL regulates TNFalpha expression through its interaction with hnRNPL</article-title>. <source/><italic toggle="yes">Proc National Acad Sci USA</italic>. <year>2014</year>;<volume>111</volume>(<issue>3</issue>):<fpage>1002</fpage>–<lpage>1007</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1313768111</pub-id></mixed-citation>
</ref>
<ref id="CIT0014">
<label>14.</label>
<mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Q</given-names></string-name>. <article-title>Long non-coding RNA THRIL promotes LPS-induced inflammatory injury by down-regulating microRNA-125b in ATDC5 cells</article-title>. <source/><italic toggle="yes">Int Immunopharmacol</italic>. <year>2019</year>;<volume>66</volume>:<fpage>354</fpage>–<lpage>361</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.intimp.2018.11.038</pub-id><pub-id pub-id-type="pmid">30521964</pub-id></mixed-citation>
</ref>
<ref id="CIT0015">
<label>15.</label>
<mixed-citation publication-type="journal"><string-name><surname>Xia</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>X</given-names></string-name>. <article-title>The long noncoding RNA THRIL knockdown protects hypoxia-induced injuries of H9C2 cells through regulating miR-99a</article-title>. <source/><italic toggle="yes">Cardiol J</italic>. <year>2018</year>;<volume>26</volume>:<fpage>564</fpage>–<lpage>574</lpage>.<pub-id pub-id-type="pmid">29745968</pub-id></mixed-citation>
</ref>
<ref id="CIT0016">
<label>16.</label>
<mixed-citation publication-type="journal"><string-name><surname>Tan</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Luo</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>W</given-names></string-name>, et al. <article-title>TNF-alpha is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma</article-title>. <source/><italic toggle="yes">EBio Med</italic>. <year>2019</year>;<volume>40</volume>:<fpage>446</fpage>–<lpage>456</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ebiom.2018.12.047</pub-id></mixed-citation>
</ref>
<ref id="CIT0017">
<label>17.</label>
<mixed-citation publication-type="journal"><string-name><surname>Zhou</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>J</given-names></string-name>. <article-title>Tumor necrosis factor alpha in the onset and progression of leukemia</article-title>. <source/><italic toggle="yes">Exp Hematol</italic>. <year>2017</year>;<volume>45</volume>:<fpage>17</fpage>–<lpage>26</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.exphem.2016.10.005</pub-id><pub-id pub-id-type="pmid">27833035</pub-id></mixed-citation>
</ref>
<ref id="CIT0018">
<label>18.</label>
<mixed-citation publication-type="journal"><string-name><surname>Lu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>TGF-beta-induced NKILA inhibits ESCC cell migration and invasion through NF-kappaB/MMP14 signaling</article-title>. <source/><italic toggle="yes">J Mol Med (Berl)</italic>. <year>2018</year>;<volume>96</volume>(<issue>3–4</issue>):<fpage>301</fpage>–<lpage>313</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00109-018-1621-1</pub-id><pub-id pub-id-type="pmid">29379981</pub-id></mixed-citation>
</ref>
<ref id="CIT0019">
<label>19.</label>
<mixed-citation publication-type="journal"><string-name><surname>Du</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yuan</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>X</given-names></string-name>, et al. <article-title>The LPS-inducible lncRNA Mirt2 is a negative regulator of inflammation</article-title>. <source/><italic toggle="yes">Nature Commun</italic>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>2049</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-017-02229-1</pub-id><pub-id pub-id-type="pmid">29230038</pub-id></mixed-citation>
</ref>
<ref id="CIT0020">
<label>20.</label>
<mixed-citation publication-type="journal"><string-name><surname>Cui</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Xie</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>Z</given-names></string-name>, et al. <article-title>The human long noncoding RNA lnc-IL7R regulates the inflammatory response</article-title>. <source/><italic toggle="yes">Eur J Immunol</italic>. <year>2014</year>;<volume>44</volume>(<issue>7</issue>):<fpage>2085</fpage>–<lpage>2095</lpage>. doi:<pub-id pub-id-type="doi">10.1002/eji.201344126</pub-id><pub-id pub-id-type="pmid">24723426</pub-id></mixed-citation>
</ref>
<ref id="CIT0021">
<label>21.</label>
<mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Xing</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Gong</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>. <article-title>Long non-coding RNA urothelial carcinoma associated 1 promotes proliferation, migration and invasion of osteosarcoma cells by regulating microRNA-182</article-title>. <source/><italic toggle="yes">Cell Physiol Biochem</italic>. <year>2018</year>;<volume>51</volume>(<issue>3</issue>):<fpage>1149</fpage>–<lpage>1163</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000495493</pub-id><pub-id pub-id-type="pmid">30481751</pub-id></mixed-citation>
</ref>
<ref id="CIT0022">
<label>22.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Fu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Yu</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ai</surname>
<given-names>F</given-names></string-name>. <article-title>Long non-coding RNA THRIL predicts increased acute respiratory distress syndrome risk and positively correlates with disease severity, inflammation, and mortality in sepsis patients</article-title>. <source/><italic toggle="yes">J Clin Lab Anal</italic>. <year>2019</year>;<fpage>e22882</fpage>.<pub-id pub-id-type="pmid">31257645</pub-id></mixed-citation>
</ref>
<ref id="CIT0023">
<label>23.</label>
<mixed-citation publication-type="journal"><string-name><surname>Xie</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>X</given-names></string-name>, et al. <article-title>Immunological cytokine profiling identifies TNF-alpha as a key molecule dysregulated in autistic children</article-title>. <source/><italic toggle="yes">Oncotarget</italic>. <year>2017</year>;<volume>8</volume>(<issue>47</issue>):<fpage>82390</fpage>–<lpage>82398</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.19326</pub-id><pub-id pub-id-type="pmid">29137272</pub-id></mixed-citation>
</ref>
<ref id="CIT0024">
<label>24.</label>
<mixed-citation publication-type="journal"><string-name><surname>Sathishkumar</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Prabu</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Mohan</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Balasubramanyam</surname>
<given-names>M</given-names></string-name>. <article-title>Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes</article-title>. <source/><italic toggle="yes">Human Genomics</italic>. <year>2018</year>;<volume>12</volume>(<issue>1</issue>):<fpage>41</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40246-018-0173-3</pub-id><pub-id pub-id-type="pmid">30139387</pub-id></mixed-citation>
</ref>
<ref id="CIT0025">
<label>25.</label>
<mixed-citation publication-type="journal"><string-name><surname>Esfandi</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Taheri</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Omrani</surname>
<given-names>MD</given-names></string-name>, et al. <article-title>Expression of long non-coding RNAs (lncRNAs) has been dysregulated in non-small cell lung cancer tissues</article-title>. <source/><italic toggle="yes">BMC Cancer</italic>. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>222</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12885-019-5435-5</pub-id><pub-id pub-id-type="pmid">30866866</pub-id></mixed-citation>
</ref>
<ref id="CIT0026">
<label>26.</label>
<mixed-citation publication-type="journal"><string-name><surname>Abdolmaleki</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ghafoui-Fard</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Taheri</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Expression analysis of a panel of long non-coding RNAs (lncRNAs) revealed their potential as diagnostic biomarkers in bladder cancer</article-title>. <source/><italic toggle="yes">Genomics</italic>. <year>2019</year>. doi:<pub-id pub-id-type="doi">10.1016/j.ygeno.2019.04.020</pub-id></mixed-citation>
</ref>
<ref id="CIT0027">
<label>27.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Z</given-names></string-name>, et al. <article-title>Association between MALAT1 and THRIL polymorphisms and precancerous cervical lesions</article-title>. <source/><italic toggle="yes">Genetic Testing Mol Biomarkers</italic>. <year>2018</year>;<volume>22</volume>(<issue>9</issue>):<fpage>509</fpage>–<lpage>517</lpage>. doi:<pub-id pub-id-type="doi">10.1089/gtmb.2018.0097</pub-id></mixed-citation>
</ref>
<ref id="CIT0028">
<label>28.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolczyk</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Zaremba-Czogalla</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hryniewicz-Jankowska</surname>
<given-names>A</given-names></string-name>, et al. <article-title>TNF-alpha promotes breast cancer cell migration and enhances the concentration of membrane-associated proteases in lipid rafts</article-title>. <source/><italic toggle="yes">Cell Oncol (Dordr)</italic>. <year>2016</year>;<volume>39</volume>(<issue>4</issue>):<fpage>353</fpage>–<lpage>363</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13402-016-0280-x</pub-id><pub-id pub-id-type="pmid">27042827</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>